Pharmacological therapies for height improvement in pubertal children with short stature

ZHU Jian-Fang; WANG Chun-Lin

doi:10.7499/j.issn.1008-8830.2309125

PDF(531 KB)

Chinese Journal of Contemporary Pediatrics ›› 2024, Vol. 26 ›› Issue (2) : 118-123. DOI: 10.7499/j.issn.1008-8830.2309125

SERIES LECTURE—STANDARDIZED DIAGNOSIS AND TREATMENT OF SHORT STATURE IN CHILDREN

Pharmacological therapies for height improvement in pubertal children with short stature

ZHU Jian-Fang, WANG Chun-Lin

Author information +

History +

Abstract

Short stature in puberty significantly affects the physical and mental health of adolescents. The continuous acceleration of skeletal maturation, caused by sex hormones during puberty, limits the time available for growth and poses a considerable challenge for the treatment of short stature. To date, there is still no standardized treatment protocol for this disorder. However, puberty is the last period to improve the final adult height. Currently, commonly used pharmacological treatments in clinical settings include recombinant human growth hormone, gonadotropin-releasing hormone analogs, and third-generation aromatase inhibitors. In recent years, personalized treatment aiming to improve the final adult height has become a key focus in clinical practice. This article provides a comprehensive summary of research on pharmacological therapies for height improvement in pubertal children with short stature, offering valuable insights for healthcare professionals.

Key words

Short stature / Recombinant human growth hormone / Gonadotropin-releasing hormone analog / Aromatase inhibitor / Puberty

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHU Jian-Fang, WANG Chun-Lin. Pharmacological therapies for height improvement in pubertal children with short stature[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(2): 118-123 https://doi.org/10.7499/j.issn.1008-8830.2309125

References

1 中华医学会儿科学分会内分泌遗传代谢学组. 矮身材儿童诊治指南[J]. 中华儿科杂志, 2008, 46(6): 428-430. PMID: 19099778. DOI: 10.3321/j.issn:0578-1310.2008.06.007.
2 Li F, Liu K, Zhao Q, et al. Prevalence of short stature among children in China: a systematic review[J]. Pediatr Investig, 2021, 5(2): 140-147. PMID: 34179712. PMCID: PMC8212717. DOI: 10.1002/ped4.12233.
3 Backeljauw P, Cappa M, Kiess W, et al. Impact of short stature on quality of life: a systematic literature review[J]. Growth Horm IGF Res, 2021, 57-58: 101392. PMID: 33975197. DOI: 10.1016/j.ghir.2021.101392.
4 Safari O, Ejtahed HS, Namazi N, et al. Association of short stature and obesity with cardio-metabolic risk factors in Iranian children and adolescents: the CASPIAN-V study[J]. J Diabetes Metab Disord, 2021, 20(2): 1137-1144. PMID: 34900767. PMCID: PMC8630324. DOI: 10.1007/s40200-021-00831-1.
5 中国广播网. 我国700万矮小患儿仅3万在治专家呼吁合力破解难题[EB/OL]. (2014-03-25)[2023-08-31]. http://politics.people.com.cn/n/2014/0325/c70731-24729489.html.
6 Mauras N, Ross J, Mericq V. Management of growth disorders in puberty: GH, GnRHa, and aromatase inhibitors: a clinical review[J]. Endocr Rev, 2023, 44(1): 1-13. PMID: 35639981. DOI: 10.1210/endrev/bnac014.
7 中华医学会儿科学分会内分泌遗传代谢学组, 中华儿科杂志编辑委员会. 过渡期生长激素缺乏症诊断及治疗专家共识[J]. 中华儿科杂志, 2020, 58(6): 455-460. PMID: 32521956. DOI: 10.3760/cma.j.cn112140-20200314-00237.
8 Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency[J]. Horm Res Paediatr, 2016, 86(6): 361-397. PMID: 27884013. DOI: 10.1159/000452150.
9 Alzahrani AK, Algethami AK, Barnawi G, et al. Differences in response to recombinant growth hormone therapy on height gain in patients with idiopathic short stature vs. patients with growth hormone deficiency[J]. Cureus, 2020, 12(3): e7319. PMID: 32313760. PMCID: PMC7164722. DOI: 10.7759/cureus.7319.
10 Gou P, Cheng X, Leng J, et al. A real-world study of recombinant human growth hormone in the treatment of idiopathic short stature and growth hormone deficiency[J]. Ther Clin Risk Manag, 2022, 18: 113-124. PMID: 35342293. PMCID: PMC8943615. DOI: 10.2147/TCRM.S363564.
11 Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society[J]. J Clin Endocrinol Metab, 2000, 85(11): 3990-3993. PMID: 11095419. DOI: 10.1210/jcem.85.11.6984.
12 Juul A, Bernasconi S, Clayton PE, et al. European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency[J]. Horm Res, 2002, 58(5): 233-241. PMID: 12401943. DOI: 10.1159/000066265.
13 中华医学会儿科学分会内分泌遗传代谢学组, 《中华儿科杂志》编辑委员会, 梁雁. 基因重组人生长激素儿科临床规范应用的建议[J]. 中华儿科杂志, 2013, 51(6): 426-432. PMID: 24120059. DOI: 10.3760/cma.j.issn.0578-1310.2013.06.007.
14 Mauras N, Attie KM, Reiter EO, et al. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group[J]. J Clin Endocrinol Metab, 2000, 85(10): 3653-3660. PMID: 11061518. DOI: 10.1210/jcem.85.10.6906.
15 Rothenbuhler A, Ormières B, Kalifa G, et al. A pilot study of growth hormone administration in boys with predicted adult short stature and near-ending growth[J]. Growth Horm IGF Res, 2015, 25(2): 96-102. PMID: 25641639. DOI: 10.1016/j.ghir.2015.01.002.
16 邓福平, 陈丹丹, 李燕燕. 不同剂量重组人生长激素对特发性矮小症患儿血清IGF-1和IGFBP-3表达的影响[J]. 中国医学创新, 2023, 20(11): 35-39. DOI: 10.3969/j.issn.1674-4985.2023.11.009.
17 郭林梅, 戴永利, 赵晓云, 等. 中国西部高海拔地区特发性矮小症男性患儿应用不同剂量rhGH治疗方案的临床疗效[J]. 兰州大学学报（医学版）, 2022, 48(6): 35-38. DOI: 10.13885/j.issn.1000-2812.2022.06.008.
18 刘运翠, 赵彤, 李文杰. 重组人生长激素联合促性腺激素释放激素类似物治疗青春期特发性矮小症女童的临床疗效[J]. 临床合理用药杂志, 2022, 15(21): 126-128. DOI: 10.15887/j.cnki.13-1389/r.2022.21.039.
19 Khawaja N, Owaineh H, Batieha A, et al. The effect of gonadotropin-releasing hormone analogue on final adult height in children with idiopathic short stature[J]. Med Princ Pract, 2019, 28(6): 509-516. PMID: 30995651. PMCID: PMC6944933. DOI: 10.1159/000499929.
20 Wit JM. Should skeletal maturation be manipulated for extra height gain?[J]. Front Endocrinol (Lausanne), 2021, 12: 812196. PMID: 34975773. PMCID: PMC8716689. DOI: 10.3389/fendo.2021.812196.
21 Bangalore Krishna K, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium[J]. Horm Res Paediatr, 2019, 91(6): 357-372. PMID: 31319416. DOI: 10.1159/000501336.
22 Hokken-Koelega ACS, van der Steen M, Boguszewski MCS, et al. International consensus guideline on small for gestational age: etiology and management from infancy to early adulthood[J]. Endocr Rev, 2023, 44(3): 539-565. PMID: 36635911. PMCID: PMC10166266. DOI: 10.1210/endrev/bnad002.
23 Li S, Wang X, Zhao Y, et al. Combined therapy with GnRH analogue and growth hormone increases adult height in children with short stature and normal pubertal onset[J]. Endocrine, 2020, 69(3): 615-624. PMID: 32533506. DOI: 10.1007/s12020-020-02375-5.
24 Dotremont H, France A, Heinrichs C, et al. Efficacy and safety of a 4-year combination therapy of growth hormone and gonadotropin-releasing hormone analogue in pubertal girls with short predicted adult height[J]. Front Endocrinol (Lausanne), 2023, 14: 1113750. PMID: 37008942. PMCID: PMC10064858. DOI: 10.3389/fendo.2023.1113750.
25 Zhou B, Liu S, Wang J, et al. A meta-analysis of combination therapy with gonadotrophin-releasing hormone agonist and growth hormone for children with idiopathic short stature and normal timed puberty[J]. Endocrine, 2022, 75(3): 698-708. PMID: 35083638. DOI: 10.1007/s12020-021-02970-0.
26 王春林, 傅君芬, 梁黎. 改善矮小儿童成年身高的药物研究进展[J]. 中国实用儿科杂志, 2020, 35(6): 460-464. DOI: 10.19538/j.ek2020060609.
27 Mauras N, Gonzalez de Pijem L, Hsiang HY, et al. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years[J]. J Clin Endocrinol Metab, 2008, 93(3): 823-831. PMID: 18165285. PMCID: PMC2266949. DOI: 10.1210/jc.2007-1559.
28 Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial[J]. J Clin Endocrinol Metab, 2005, 90(12): 6396-6402. PMID: 16189252. DOI: 10.1210/jc.2005-1392.
29 李燕虹, 杜敏联, 马华梅, 等. 来曲唑改善青春期特发性身材矮小症男性患儿成年身高的疗效评价[J]. 浙江大学学报（医学版）, 2020, 49(3): 308-314. PMID: 32762161. PMCID: PMC8800791. DOI: 10.3785/j.issn.1008-9292.2020.04.05.
30 Wang S, Wu Z, Chen Y, et al. Comparative efficacy of aromatase inhibitors and gonadotropin-releasing hormone analogue in increasing final height of idiopathic short stature boys: a network meta-analysis[J]. Front Endocrinol (Lausanne), 2023, 14: 1167351. PMID: 37124748. PMCID: PMC10140494. DOI: 10.3389/fendo.2023.1167351.
31 王冬妮, 武苏, 刘倩琦. 芳香化酶抑制剂治疗青春期矮身材疗效及安全性研究进展[J]. 儿科药学杂志, 2023, 29(6): 56-60. DOI: 10.13407/j.cnki.jpp.1672-108X.2023.06.015.
32 Varimo T, Toiviainen-Salo S, Raivio T, et al. Letrozole monotherapy in pre- and early-pubertal boys does not increase adult height[J]. Front Endocrinol (Lausanne), 2019, 10: 201. PMID: 31024444. PMCID: PMC6460933. DOI: 10.3389/fendo.2019.00201.
33 Hero M, Toiviainen-Salo S, Wickman S, et al. Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty[J]. J Bone Miner Res, 2010, 25(7): 1536-1543. PMID: 20200972. DOI: 10.1002/jbmr.56.
34 Mauras N, Ross JL, Gagliardi P, et al. Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short stature[J]. J Clin Endocrinol Metab, 2016, 101(12): 4984-4993. PMID: 27710241. PMCID: PMC5155684. DOI: 10.1210/jc.2016-2891.
35 崔蕴璞, 王新利. 来曲唑治疗青春期特发性矮身材男童的临床观察[J]. 中国当代儿科杂志, 2019, 21(10): 977-982. PMID: 31642430. PMCID: PMC7389739. DOI: 10.7499/j.issn.1008-8830.2019.10.005.
36 孔元梅, 陈虹, 梁黎, 等. 芳香化酶抑制剂联合生长激素治疗青春期身材矮小症男性患儿的临床研究[J]. 浙江大学学报（医学版）, 2020, 49(3): 283-290. PMID: 32762170. PMCID: PMC8800756. DOI: 10.3785/j.issn.1008-9292.2020.04.06.
37 王春林, 梁黎. 第三代非甾体类芳香化酶抑制剂在儿科内分泌临床应用的再认识[J]. 浙江大学学报（医学版）, 2020, 49(3): 275-282. PMID: 32762160. PMCID: PMC8800707. DOI: 10.3785/j.issn.1008-9292.2020.04.01.